Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 30, 2026
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)
TOKYO, June 30, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release today regarding Enspryng® (satralizumab), stating that the U.S. Food and Drug Administration (FDA) has accepted its application for the treatment of thyroid eye disease (TED).
Please refer to the link below for details of the media release:
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
https://www.roche.com/media/releases/med-cor-2026-06-30
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Naoki Kouzai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp